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Abstract
Postoperative pancreatic fistula is a major surgical complication that can follow pancreatic resection. Postoperative
pancreatic fistula can develop as a consequence of leaking pancreatic fluid, which calls for an intraoperative indicator of
leakage. But suitable indicators of pancreatic leakage have yet to be found. This study details the evidence-based
development and early efficacy assessments of a novel pancreatic leakage indicator (SmartPAN), following the IDEAL
framework of product development. We developed 41 SmartPAN prototypes by combining indicators of pancreatic fluid
with a polysaccharide-microsphere matrix. The prototypes were assessed in vitro using porcine (Sus scrofa domesticus)
pancreatic tissue and ex vivo with human pancreatic fluid. From these initial tests, we chose a hydrogel-based compound
that uses the pH indicator bromothymol blue to detect alkali pancreatic fluid. This prototype was then assessed in vivo
for usability, effectiveness and reliability using a porcine model. Treatment groups were defined by SmartPAN-reaction at
initial pancreatic resection: indicator-positive or negative. Indicator-positive individuals randomly received either tar-
geted closure of leakage sites or no further closure. We assessed SmartPAN’s reliability and effectiveness by monitoring
abdominal drainage for amylase and with relaparotomy after 48 h. SmartPAN responses were consistent between both
surgical procedures and conformed to amylase measurements. In conclusion, we have developed the first surgery-ready
indicator for predicting the occurrence of pancreatic leakage during pancreatic resection. SmartPAN can enable targeted
prophylactic closure in a simple and reliable way, and thus may reduce the impact of postoperative pancreatic fistula by
guiding peri- and post-operative management.
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Introduction
Pancreatic resection (PR) is now widely regarded as a
routine surgical procedure, with an estimated 40,000
annual operations in the United States.1 PR is per-
formed to treat a variety of malignant and benign con-
ditions of the pancreas and can be combined with
adjuvant chemotherapy to improve survival in patients
with pancreatic adenocarcinoma.2,3 Yet despite broad
and consistent improvements, PR is still associated
with appreciable morbidity and mortality.4 An impor-
tant complication is the development of postoperative
pancreatic fistula (POPF), which involves leakage of
enzyme-rich pancreatic fluid from the surgical remnant
or anastomosis. This leakage can lead to the break-
down of intra-abdominal tissue and result in sepsis,
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hemorrhage or death.5,6 POPF has been reported to
affect up to 45% of patients following PR, and is asso-
ciated with expensive hospital stays and significant eco-
nomic burdens.7–13
High concentrations of pancreatic enzymes in fluid
from the peripancreatic environment are highly predic-
tive of POPF development after pancreaticoduodenec-
tomy and distal pancreatectomy.14,15 The pancreatic
parenchyma is delicate and therefore requires a fastid-
ious surgical technique to close the remnant or perform
anastomosis. Leakage of pancreatic fluid during early
recovery is considered to be caused by intraoperative
factors such as disruption of pancreatic ducts or incom-
plete closure of the pancreatic remnant.5,6,16 However,
it is difficult to identify potential pancreatic leaks
during surgery as the fluid is clear and seeps from
microscopic openings into a moist environment.
Thus, identifying and localizing pancreatic leakage
would likely optimize peri- and post-operative manage-
ment, including placement of drains, targeted closure,
and proper postoperative care. Consequently, the
extent of pancreatic fluid leakage and the risk of
POPF may be reduced.
At present, there are no reliable ways to predict
POPF, take prophylactic peri-operative measurements
or perform targeted closure during surgery.16 Some
attempts have been made to develop a method for
intraoperative identification of pancreatic fluid leak-
age,17–21 but none are clinically useful. The ideal indi-
cator of pancreatic fluid leakage would show high
sensitivity and specificity in situ with a clear and dis-
cernible reaction. Further, it would be quick and easy
to use in an operating environment, requiring basic
training. Other essential characteristics include a dura-
ble and localized response, absence of toxicity, and low
cost. In this study, we describe the development of a
reliable intraoperative pancreatic fluid leakage indica-
tor (SmartPAN) that may facilitate targeted closure of
the pancreatic remnant and allow prediction of POPF
development.
Methods
The study was performed in two parts, using the
IDEAL Framework for product development (Idea,
Development, Exploration, Assessment, Long-term
monitoring).22–24 Part 1 covers the refinement of an
effective pancreatic fluid indicator (SmartPAN). Our
biomaterial is based on a microsphere-hydrogel-
carrier-matrix that accurately locates leaks by exploit-
ing the alkali pH of pancreatic fluid. We developed
a proof-of-concept for SmartPAN with in vitro and
ex vivo experimentation. Part 2 covers a 48-hour
in vivo evaluation of usability, effectiveness, and
safety using a porcine model (Sus scrofa domesticus).
Part 1: Identification, refinement, and preliminary
testing of SmartPAN
Assessing candidate indicators. We tested four different
substances for use as the active indicator (Table 1).
The Phadebas! amylase test (Phadebas, Kristianstad
Sweden) and tri-iodide-starch solution (Pharmacy
Department, Heidelberg University Hospital) were
selected because they identify amylase, a natural com-
ponent of pancreatic fluid. Bromothymol blue (BTB)
and phenolphthalein were selected because they are
indicators of alkali solutions, as pancreatic fluid
has a pH of 8.0–8.3 whilst human blood has approxi-
mately 7.4.25
We applied these indicators in their raw form to (i)
saliva-moistened filter paper (n¼ 3 per indicator; 1mL
indicator applied),26 (ii) fresh porcine pancreatic tissue
obtained from slaughterhouse pigs (n¼ 5 per indicator;
2–3mL SmartPAN per slice in a homogenous layer),
(iii) human pancreatic fluid obtained from surgery
(n¼ 3 per indicator; 2mL SmartPAN applied to
100 lL pancreatic fluid on 3 3 cm2 gauze), and (iv)
in vivo using pigs (n¼ 10, indicators applied haphazard-
ly). Indicator responses were qualitatively evaluated
in situ for (i) contrast of color change against the back-
ground, (ii) visual resolution (amount of pancreatic
fluid needed for visualization), (iii) time-to-reaction
(shorter is better), and (iv) practical handling. Based
on these trials, we selected BTB as the active indicator.
The polysaccharide-microsphere-carrier-matrix. SmartPAN
was created by combining the active indicator (BTB)
with a cross-linked potato-starch derived polysaccharide-
microsphere-matrix (Magle Chemoswed, Malm€o,
Sweden), specially designed to absorb and electrostati-
cally bind to the indicator (Figure 1; Table 2). The
microspheres were prepared with a water-in-oil emul-
sion technique, using epichlorohydrin as a cross-linking
agent. The polysaccharide microspheres have a dual
function as a carrier for the indicator and as a struc-
tural vehicle to concentrate reactions at leakage sites.
That is, the microspheres rapidly concentrate aqueous
pancreatic fluid, due to the hydrophilic nature of
starch, and expose the dissolved constituents to the
indicator. Upon contact with alkali pancreatic fluid,
the indicator reacts with a rapid and intense color
change that visualizes pancreatic fluids close to the
site of origin. Because the indicator has low solubility
it does not osmotically shift from the matrix, thereby
allowing localized reactions. Following use, the micro-
spheres degrade through enzymatic action to biocom-
patible glucose within minutes.
We provide a chemical characterization of the
microspheres in the Supplementary Information. In
brief, we used magic angle spinning nuclear magnetic
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resonance, X-ray powder diffraction, and scanning
electron microscopy. These techniques demonstrate
that the microspheres are a hydrolyzed, glucose-
based, carbohydrate polymer based on starch. The
microspheres are less rigid than native starch, and bio-
degrade faster owing to their amorphous structure. The
chemical compound forms a smooth sphere with a
diameter of 200–250 mm.
Refining the indicator prototype. We tested the BTB–
microsphere compound with wipe, tape, powder, and
hydrogel applicators, resulting in 20 different
SmartPAN prototypes (SmartPAN 001–020, details
available upon request). The prototypes were assessed
(i) in vitro on slices of freshly resected porcine pancreas
during surgery (n¼ 5 per indicator; 2–3mL SmartPAN
per slice in a homogenous layer), (ii) ex vivo with fresh
human pancreatic fluid (n¼ 3–12 per indicator; 2mL
SmartPAN applied to 100 lL pancreatic fluid on
3 3 cm2 gauze), and (iii) in vivo with pigs (n¼ 10;
4mL SmartPAN applied to freshly resected pancreatic
stump). Representative images of testing are given in
Figure 2.
The prototypes were assigned a subjective perfor-
mance rating of 0 (undesirable) or 1 (desirable) by the
attending surgeon for: (i) handling (desirable com-
pounds are easy to use, homogenous and viscous
enough to remain in place), (ii) reaction time (desirable
compounds react within seconds), (iii) power
(desirable compounds have an intense reaction without
background interference), (iv) precision (desirable com-
pounds react only over leakage sites), (v) durability
(desirable compounds maintain their structure and
have a stable, persistent, and localized color
change for many minutes). We summed these scores
for a total performance rating out of 5 and
selected the best as a “gold standard” to use through-
out the remainder of the trials. We developed a fur-
ther 21 subtypes from the gold standard (SmartPAN
021–041) and tested them in vitro with porcine pancre-
atic tissue to ensure homology among types (n¼ 5 per
indicator).
Figure 1. Microsphere-matrix mode of action. (a) Sponge-like polysaccharide microspheres with bromothymol blue (BTB) bound to
its surface and within its matrix. (b) Immediate surface color change in reaction to alkali pancreatic fluid. (c) Pancreatic fluid reaches
the microsphere core and the indicator within, causing local fixation and intensification of the reaction within microseconds.
(d) Pancreatic amylase hydrolyses the polysaccharide matrix of biocompatible SmartPAN within minutes. Photo credits TP. The faded
background microsphere shows an original electron microscope photo of the microsphere courtesy of Magle Chemoswed, Malm€o,
Sweden.
Table 1. Substances tested as indicators of pancreatic fluid.
Indicator Responds to Color change Mode of action
Phadebas Amylase Test! Amylase Clear to blue Cleavage of dye from the starch matrix by amylase
Triiodide-starch solution Amylase Blue to clear Cleavage of starch in tri-iodide-starch-complex by amylase
Bromothymol blue (BTB) pH >7.6 Yellow to green/blue Deprotonation
Phenolphthalein pH >8.2 Clear to pink Deprotonation
Pausch et al. 125
SmartPAN gold standards. The final SmartPAN hydrogel
prototype was created by mixing 121 g (746 mMol,
based on the monomeric unit) of dry microspheres
with 121mL of 0.3% BTB/ethanol solution and
drying overnight at 60C in a vacuum oven. A total
of 15 g of the dry mixture was then swelled in 83mL
of saline, containing 1.5mL of 1Mol phosphate buffer
(pH¼ 5.8) per liter saline. The pH was adjusted to 4.5–
4.7 with 0.1Mol HCl acid. We measured the pH of the
gel during and after the addition of saline/buffer with a
pH electrode in a sediment mixture of 1.0 g of gel and
5.0mL of purified water. We measured the buffer
capacity of the gel after the addition of saline/buffer
by treating the mixture with 3.60mL of 0.001Mol
NaOH that had been allowed to sediment. Sterilized
compounds were created by steam autoclaving
hydrogel-filled syringes. This did not change the pH
or consistency of the gel but did slightly increase the
buffer capacity.
As part of the product development, we qualitatively
and subjectively compared SmartPAN to potentially
equivalent products in the literature following the guide-
lines from the European Commission for the develop-
ment of medical devices.27 We find that there are similar
products, but none that are fully equivalent to
SmartPAN (Table 3; full results available upon request).
Part 2: In vivo assessment of SmartPAN usability
and effectiveness
Animal treatment groups. Ten pigs underwent distal pan-
createctomy as described below, and the pancreatic
Table 2. Particle characteristics and in vivo surgical performance scores for the four gold standard SmartPAN subtypes. All subtypes
have gel-like surface properties when swollen in aqueous solution. They may also have a slightly negative surface charge from hydroxyl
groups. Particles degrade in 4–24 h.
Property SmartPAN 016 SmartPAN 026 SmartPAN 032 SmartPAN 039
Applicator Gel Gel Gel Gel
Starch-matrix concentration (%w/w) 16.7 14.9 15.3 14.7
Particle size range (lm) 50–1200 50–1200 50–1200 32–900
Particle shape Spherical Spherical Spherical Spherical
Degree of crosslinking (mol %) 26 26 26 27
Buffered Y Y Y Y
Buffer concentration (mMol) 18 6.6 1.5 1.4
Indicator concentration (%w/w) 0.050 0.045 0.045 0.044
Ion strength (mMol) 190 167 157 157
pH 4.7 4.8 4.5 4.4
Sterilized N Y Y Y
Performance: handling 1 0 1 0
Performance: reaction time 1 1 1 1
Performance: power 1 0 1 1
Performance: precision 1 1 1 1
Performance: durability 1 1 1 1
Performance: total 5 3 5 4
Figure 2. Testing SmartPAN prototypes: (a) powder in vivo; (b) tape in vivo; (c) hydrogel in vitro. Photo credits TP.
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remnant was assessed for pancreatic leakage after clo-
sure. The animals were grouped according to indicator
reaction: “indicator-positive” (n¼ 9) and “indicator-
negative” (n¼ 1). Animals in the “indicator-positive”
group were randomly sub-grouped by coin toss into
two groups based on whether the leakage was left
uncorrected (leakage-uncorrected; n¼ 7), or treated
with targeted closure using extra sutures (leakage-cor-
rected; n¼ 2). This resulted in three study groups, sum-
marized in Table 4. In order to minimize inter-observer
variance, indicator responses were agreed upon by the
entire operation team present during each procedure.
Confirming SmartPAN usability in vivo over 48 h. The usabil-
ity of the four gold standard SmartPAN formulations
(SmartPAN 016, 026, 032, 039) was assessed in vivo
with distal pancreatectomy. Following the operation,
we conducted a clinical and laboratory follow-up
assessment of pancreatic leakage by measuring
enzyme levels in blood serum and abdominal drainage
fluid. Abdominal fluid and blood samples were
obtained from the study animals at the initial operation
on day 0 and again on the mornings of days 1 and 2.
Immediate analysis was performed at the central labo-
ratory of Heidelberg University Hospital.
According to the guidelines of the International
Study Group of Pancreatic Fistula (ISGPF), pancreatic
leakage in humans can be predicted by blood serum
amylase values 3 times the upper normal serum
level at day 3 after surgery.6 Because serum amylase
levels vary significantly between different breeds and
ages of pig, we calculated a mean value of all day 0
readings to serve as a “normal” amylase level. We then
calculated the ratio of abdominal drainage fluid:
normal serum amylase content for each pig, and con-
sidered values 3 as indicative of potential leakage. As
this study was only 48 h, these data are presented only
as supporting evidence for leakage rather than a true
diagnosis for leakage or POPF.
After 48 h of follow-up, the pigs were relaparotom-
ized by removing sutures and assessed for intra-
abdominal complications such as ascites, adhesions,
signs of infection, and bleeding. The stump of the pan-
creatic remnant was closely assessed for signs of infec-
tion, bleeding, pancreatitis, and inadequate closure. We
then reapplied SmartPAN to the surface of the pancre-
atic remnant. The animals were euthanized at the end
of the experiment by central venous application of
potassium-chloride whilst conducing deep narcosis
and analgesia.
Surgical procedure: Distal pancreatectomy
and closure
The same surgeon operated in all cases to ensure stan-
dardization of technique. Distal pancreatectomy was
performed under general anaesthesia in semi-sterile
conditions. A central venous catheter was placed into
the jugular vein for postoperative blood sampling
and administering medication. An upper median
Table 3. Equivalent products for detecting pancreatic leakage.
Clinical, technical, and biological equivalence scored as 1:
doubtful equivalence, 2: probable equivalence, 3: high equiva-
lence, following MEDDEV guidelines.27 Level of evidence (LoE)
scored according to guidelines from the American Heart
Foundation, with 1 being the highest and 8 being the lowest.28 A
score of 3 indicates a prospective, nonrandomized controlled
study, and a score of 6 indicates animal experimental studies,
mechanistic models, or in vitro studies. N refers to the number of
subjects studied.
Equivalence
Product Clinical Technical Biological LoE N
Bromothymol blue29 2 2 2 3 46
Litmus paper20 3 2 1
Fluorescent
probe 18,19,21
3 2 1 6 30
FRET-based
nanoprobe17
3 2 1 6 6
FRET: F€orster resonance energy transfer.
Table 4. Surgical assessment and treatment group assignment following application of SmartPAN at initial surgery.
Treatment group SmartPAN subtype Indicator reaction
Group 1 (n¼ 7): leakage-uncorrected 16 Leakage at one site mid-stump
26 Small leak adjacent to the cranial suture
32 Light but diffuse leakage
39 Leakage at two sites cranial-stump
39 Leakage at two sites cranial-stump
39 Leakage at cranial and mid-stump
39 Diffuse light leakage
Group 2 (n¼ 2): leakage-corrected 16 Leakage at caudal-stump
26 Two leakages adjacent to original sutures
Group 3 (n¼ 1): indicator-negative 32 No leakage
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laparotomy incision and opening of the omental bursa
exposed the pancreas. Scissors were used to release the
splenic lobe (2–3 cm from the pancreas edge) from the
surrounding peritoneal tissue and renal fascia.
Pancreatic tissue was then resected using a scalpel,
sliced and immediately used for ex vivo experimenta-
tion. Pancreatic hemostasis was achieved using a max-
imum of three single/x-stitch, nonabsorbable sutures.
The pancreatic stump was closed using transverse, non-
absorbable single sutures (1 suture/cm tissue), and then
rinsed with sterile saline and dried with sterile gauze.
Indicator prototypes were applied to the pancreatic
stump (Figure 3). Prior to application, the operative
field was gently rinsed and dabbed to free the area
from fluids that might reduce effectiveness. The pres-
ence of water moisture did not appear to impair
SmartPAN function. The tissue of interest was main-
tained in a horizontal position and approximately 4mL
of SmartPAN was applied rapidly and uniformly to the
cut surface from above, taking care to prevent over-
spill. It was not necessary to rinse the SmartPAN
unless its presence hindered surgical procedure.
Pigs used for the in vivo component of Part 1
received no further treatment after SmartPAN applica-
tion and were euthanized after testing. For Part 2, a
closed suction drain (Jackson PrattVR ) was placed next
to the pancreatic stump and passed through the sub-
costal abdominal wall to evacuate peritoneal fluid and
use it for further analysis. Pigs that expressed a
positive-indicator response and were assigned to the
leakage-corrected group received a fine-closure of the
stump using one targeted nonabsorbable single/x-stitch
suture. The effectiveness of closure was then tested with
reapplication of SmartPAN. Pigs in the leakage-
uncorrected group received no targeted closure. We
finished the operation by closing the abdominal wall
Figure 3. Directions for SmartPAN application. (a) Remove applicator from packaging. (b) Prepare the application site by exposing
the organ, performing hemostasis, and cleaning away blood and liquid by rinsing and dabbing. (c) Apply SmartPAN in one continuous
layer to the tissue surface, keeping the applicator jet pointed downward. Move the applicator back and forth over the tissue in an
S-shaped pattern. (d) Check for indicator reaction. If negative, remove SmartPAN by rinsing with sterile isotone saline, and reapply for
verification. (e) If indicator is positive, perform targeted surgical closure. (f) Reapply SmartPAN to confirm closure. (g) Rinse the
surgical site and remove SmartPAN fluid with drainage or suctioning. Images courtesy of Magle Chemoswed, Malm€o, Sweden.
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with continuous suturing of the fascia and skin. At 48 h
after surgery, pigs were relaparotomized for clinical
evaluation and re-application of SmartPAN, then
euthanized.
Materials and subjects
Procurement of porcine pancreatic tissue and human
pancreatic fluid. Porcine pancreatic tissue was
donated by a local slaughterhouse
(Fleischversorgungszentrum, Mannheim) within 12 h
post-mortem, and stored at 2C until required (see
Part 1: Assessing candidate indicators). We also used
resected tissue from in vivo experiments for immediate
in vitro testing (see Part 1: Refining the indicator
prototype).
The human pancreatic fluid was retrieved from fresh
surgical specimens for immediate use, after first obtain-
ing informed consent from the patient in accordance
with the Declaration of Helsinki (approved by
Heidelberg University Ethics Committee; votes 301/
2001, 159/2002). A series of four patients received par-
tial pancreatectomy due to malignant pancreatic
tumors and we aspired fluid from surgical specimens
for testing next to the operation table.
Porcine subjects. Twenty female German domestic pigs
(Sus scrofa domesticus) were used in this experiment
due to their close anatomic and metabolic homology
to humans. The animals were approximately 30 kg in
weight and threemonths of age. Their physical and
clinical well-being was monitored closely throughout
the trial by trained animal keepers and veterinarians.
The animal experiments performed in this study were
governmentally approved according to German regu-
lations of the Animal Welfare Act (TierSchG
§ 8 Abs.1), and Regierungspr€asidium Karlsruhe (File
35–9185.81/G-184/16). We adhered to all applicable
codes of practice for the housing, care and humane
killing of animals used in scientific procedures.
Statistical analysis. We used SPSS (IBM Corp. Released
2017. IBM SPSS Statistics for Windows, Version 25.0.
Armonk, NY: IBM Corp.) for statistical analysis of
abdominal drainage fluid data. Differences in amylase
concentration between groups were assessed with a
Kruskal–Wallis test for omnibus comparison, followed
by exact Mann–Whitney U tests with a Bonferroni cor-
rection for pairwise comparisons. We considered
p< 0.05 (0.017 with correction) as statistically signifi-
cant. We recorded missing values in cases where ani-
mals did not yield sufficient drainage fluid or central
venous blood for laboratory analysis. We also calculat-
ed sensitivity and specificity for the predictive qualities
of SmartPAN.
Results
Part 1: Identification, refinement, and preliminary
testing of SmartPAN
Assessment of candidate indicators. We summarize the test
results and conclusions of candidate indicators for
SmartPAN in Table 5. Based on these findings, the
pH indicator BTB was selected as the most appropriate
indicator to combine with the polysaccharide-micro-
sphere-matrix.
Refining the indicator prototype. We developed SmartPAN
by combining BTB with the polysaccharide-
microsphere-matrix. The resultant product is a gel-
like substance that expresses local color change from
yellow to green/blue upon exposure to pancreatic fluid
(Figure 4). Powders were difficult to handle, were too
thick and were washed away by pancreatic fluid.
Similarly, powdered tape also washed away.
Table 5. Performance of pancreatic fluid indicator candidates.
Indicator Result Conclusion
Phadebas Amylase Test! Clear blue coloration specific to pancreatic fluid in vitro
and in vivo. But only indirect coloration on the back
of carrier sheets due to technical reasons.
No precise localization of pancreatic
leakage possible.
Triiodide-starch solution Specific color change for pancreatic fluid in vitro and
in vivo. Direct reaction on pancreatic tissue. But an
unfavorable color change from black to colorless
fluid is hard to discriminate.
Does not enable clear visualization of
pancreatic leakage.
Phenolphthalein Specific color change for pancreatic fluid in vitro and
in vivo. But unfavorable color change to pink above
flesh is hard to discriminate.
Does not enable clear visualization of
pancreatic leakage in vivo.
Bromothymol blue Clear color change from yellow to green/blue for
pancreatic fluid in vitro and in vivo. The effect is rapid
and contrasts with surrounding body fluids.
Provides a clear and localized indication
of pancreatic leak during surgery.
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Wipers were also ineffective, as they required a lot of
pancreatic fluid to display a reaction. Prototypes that
used a hydrogel applicator showed the best results,
after refining the biomaterial properties (results avail-
able upon request).
The hydrogel-based SmartPAN 016 showed the
greatest effectiveness of the 20 initial prototypes, pro-
viding a distinct localized color change with high visual
resolution (small amounts of pancreatic liquid are
needed for a clear color change). The reaction occurred
in a short space of time and was sustained for a period
>5min (Figure 5). SmartPAN 016 achieved a total per-
formance score of 5/5 (Table 2). The full results of these
tests are available upon request.
We conducted swelling experiments to determine
how much liquid the microspheres can absorb.
The SmartPAN microsphere compound had a swelling
capacity of 9mL/g in purified water and 7.5mL/g in
isotone-saline. 90% of the swelling occured within the
first 60 s, and no more swelling occured after 1 h.
Regarding the formulation of SmartPAN, there was
a trend in buffer capacity and performance. Gels that
had a buffer pH of 7.0–7.2 reacted quickly, whilst gels
with pH >7.2 overreacted and those with pH<7.0 were
slow. For optimal indication, the pH of the gel should
be 4.4–4.6 and have a buffer capacity of pH 7.0–7.2.
Unbuffered compositions were less precise with leakage
detection. Further, compositions with high buffer
strength provided somewhat slow detection, whereas
buffer strengths of 1–10 mMol provided quick and pre-
cise leakage detection. We found that a degree of cross-
linking around 26% Mol provided the composition
Figure 4. Identification of artificial leakage from local deposits of pancreatic fluid using SmartPAN hydrogel. Images courtesy of Magle
Chemoswed, Malm€o, Sweden.





5 s 10 s 20 s 60 s 180 s 300 s
Figure 5. Ex vivo reactions of SmartPAN 016 on gauze over 300 s following application of a droplet of: (a) 100 lL fresh human
pancreatic fluid or (b) 100 lL saline (NaCl 0.9%). Photo credits TP.
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with proper resistance to amylase degradation (i.e.
stability for >5min). Furthermore, the amount of
microspheres in the composition affects the viscosity
of the composition. It was concluded that <10% w/w
microspheres resulted in compositions that were too
liquid, whereas >20% w/w were too thick. However,
a concentration of 13–18% w/w provided a composi-
tion that was easy to handle and reacted quickly.
We preferred to keep the BTB concentration as low
as possible, but sufficiently high enough to provide
clearly visible leakage detection. A concentration of
BTB <0.04% w/w provided somewhat weak, but visi-
ble coloration.
At the conclusion of these trials, we designated
SmartPAN 016 as the “gold standard”. We further
developed 21 subtypes of SmartPAN 016 (SmartPAN
021–041), which were reassessed in vitro to ensure
homology with SmartPAN 016 (results available
upon request). We highlight four subtypes that
showed desirable performance and homology with
SmartPAN 016 in vitro. We hence classed them as
equivalent to the gold standard and carried all four
formulations to Part 2 (Table 2).
We also conducted preliminary in vitro cytotoxicity
tests using HPDE and FAMPAC cells (results available
upon request, article in preparation). These tests indi-
cated that BTB had no toxicological effects on pancre-
atic cells up to three times the concentration found in
SmartPAN.
Part 2: In vivo assessment of SmartPAN usability
and effectiveness
Confirmed usability of SmartPAN gold standard in vivo.
The in vivo surgical usability scores for the four sub-
types are shown in Table 2. All four subtypes scored
overall usability scores 3, reaffirming the perfor-
mance of SmartPAN 016 as an indicator for pancreatic
fluid and demonstrating sufficient homology between
subtypes. Importantly, SmartPAN gold standards
were deemed biocompatible and nontoxic in the con-
text of this experiment. Specifically, the only nonphy-
siologically degradable compound is BTB, which was
not detectable in abdominal drainage after 48 h (results
available upon request, article in preparation). We
believe that BTB is rapidly evacuated via surgical
drainage. The microspheres, by contrast, are designed
to biodegrade into glucose.
Treatment groups differ in abdominal amylase levels. The
amylase content of the abdominal drainage fluid was
measured on days 0, 1, and 2 to monitor for signs of
pancreatic leakage (Table S1). Kruskal–Wallis
tests indicated that there were no significant differences
in amylase content between groups on any day
(day 0: H1¼ 2.00, n¼ 5, p¼ 0.157, only missing
values for group 2; day 1: H2¼ 5.73, n¼ 10,
p¼ 0.057; day 2: H2¼ 2.49, n¼ 9, p¼ 0.288).
However, the mean amylase content of drainage fluid
was greatest in treatment-uncorrected pigs on days 1
and 2 post-operation, although not significantly after
Bonferroni correction (Figure 6; Table 6). There were
no significant differences in amylase content between
treatment-corrected and indicator-negative pigs on
days 1 or 2 (Figure 6; Table 6).
The baseline serum amylase level for this study
was established to be 2178.6U/L (min¼ 1335U/L,
max¼ 3303U/L). This value was used to calculate
ratios of abdominal drainage amylase: normal serum
amylase, which can indicate the presence of pancreatic
leakage (Table S1). Leakage-uncorrected pigs had
ratios 3 for 7/7 pigs on day 1 and 3/6 pigs on day
2. By contrast, no leakage-corrected pig had values 3
on day 1 (0/2), but 1/2 had a ratio indicative of pan-
creatic leak at day 2. No values 3 were observed in
the indicator-negative pig (0/1) throughout the
experiment.
The sensitivity and specificity of SmartPAN in pre-
dicting the likelihood of pancreatic leak are shown in
Table 7. Overall, the sensitivity of SmartPAN was
100% over days 1 and 2, while specificity dropped
from 100% to 25% between days.
Reassessment of indicator reaction at 48 h. All pigs under-
went a second laparotomy and re-evaluation of their
peritoneal cavity at 48 h. All animals in treatment





















Figure 6. Mean SE amylase levels (U/L) in abdominal drainage
for treatment groups pre-pancreatectomy (day 0) and for two
days post-pancreatectomy (black: indicator-negative; med grey:
leakage-corrected; light grey: leakage-uncorrected).
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ascites, intra-abdominal abscess formation, and adhe-
sions. These features were absent in Groups 2 and 3.
Figure 7 shows perioperative photographs of the pan-
creatic remnants of representative pigs from each of the
study groups at initial surgery (day 0) and upon lapa-
rotomy (day 2). Reapplication of SmartPAN confirmed
that all animals in Group 1 continued to leak from
their original sites. By contrast, we did not detect pan-
creatic leakage in Groups 2 and 3, nor were there any
signs of pancreatitis, inflammation, and postoperative
hemorrhage.
Discussion
Pancreatic fluid is a crucial factor in the pathogenesis
of postoperative pancreatic fistula (POPF), a major
complication of PR. In the present study, we have
detailed the development and early efficacy assessments
of SmartPAN, a novel indicator of pancreatic fluid
leakage designed for intraoperative use. The BTB-
based hydrogel indicator takes advantage of the
alkali pH of pancreatic fluid to visualize leaks following
PR. Early in vivo experiments using a porcine model
suggest that SmartPAN may reliably identify pancreat-
ic leaks intraoperatively, facilitating targeted closure of
the pancreatic remnant that stems fluid leakage for at
least 48 h.
A clinically effective and usable indicator of pancre-
atic leakage should display the following properties: (i)
a fast, durable and localized response, (ii) a clearly
Table 6. Mann–Whitney pairwise comparisons of amylase content in drainage fluid at pre-operative day 0 and for two days post-
pancreatic-resection. Comparison of medians is given in italics above the statistics.
Day Group 1 vs. 2 Group 1 vs. 3 Group 2 vs. 3
0 NA 1690 vs. 553 NA
U5¼ 0.00, p¼ 0.400
1 11,345 vs. 3388 11,345 vs. 3364 3388 vs. 3364
U¼ 0.00, n¼ 9, p¼ 0.560 U¼ 0.00, n¼ 8, p¼ 0.250 U¼ 1.00, n¼ 3, p¼ 1.000
2 7019.5 vs. 5403.5 7019.5 vs. 2356 5403.5 vs. 2356
U¼ 5.00, n¼ 8, p¼ 0.857 U¼ 0.00, n¼ 7, p¼ 0.286 U¼ 0.00, n¼ 3, p¼ 0.667
Table 7. Sensitivity and specificity of SmartPAN for predicting
the occurrence of pancreatic leaks. Leaks are diagnosed based on
drainage amylase level: normal serum amylase 3 (Table S1).
Day 1 Day 2
Leak No leak Leak No leak
Indicator þve 7 0 3 3
Indicator ve 0 1 0 1
Sensitivity 7/(7þ 0)¼ 1.00 3/(3þ 0)¼ 1.00













Figure 7. Representative images of perioperative porcine
pancreatic remnants following distal pancreatectomy pre-
and post-SmartPAN application on days 0 and 2. (a) Group 1
(leakage-uncorrected); (b) Group 2 (leakage-corrected);
(c) Group 3 (indicator-negative). SmartPAN color change
(blue) was consistent between day 0 and day 2 in all animals.
Photo credits TP.
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discernible color change, (iii) ease of use, (iv) high sen-
sitivity and specificity, (v) nontoxicity. However,
research and development of appropriate indicators
to date have been limited. In 1998, a study group
from Kyushu University, Japan applied red litmus
paper to the cut surface of the human pancreas to visu-
alize alkali pancreatic fluid.20 Although too crude a
method to be clinically useful, the researchers suggested
that a similar technique might have an application for
the identification and closure of transected pancreatic
ducts. More recent studies by a group at the University
of Tokyo18,19,21 focused on the development of fluores-
cent probes that are activated by enzymes present in
pancreatic fluid. Whilst their probes were able to visu-
alize the presence of pancreatic leaks intraoperatively,
the procedure requires substantial material and practi-
cal costs including installation of a specialist light
source, light-blocking glasses and darkening of the
operating theatre. These properties make the technique
unattractive for routine usage. Finally, another team
from Kyushu University17 devised a F€orster resonance
energy transfer (FRET) heat-shock protein probe.
Again, excitation of the probe and detection of the
FRET signal require specialist equipment not readily
available in most operating theatres. Finally, only the
fluorescent probe method was shown to work directly
in vivo at the surgical field rather than indirectly
ex vivo.19
The gold standard SmartPAN prototypes developed
here appear to provide a less complicated approach to
identify and localize pancreatic leaks. The hydrogel is
easy to handle and apply, and results in a rapid, local-
ized, and durable color change upon exposure to pan-
creatic fluid. The color change is obvious and contrasts
with intra-abdominal contents. Furthermore, our stud-
ies demonstrate that indicator reactions are consistent
over a 48-hour timeframe. Close clinical observation
and monitoring throughout this short study suggest
that SmartPAN does not cause local or systemic toxic-
ity, acknowledging that we flushed almost all the gel
from the abdominal cavity. It should be mentioned that
BTB is not considered to be toxic at the concentrations
used (see the respective Material Safety Data Sheet).
However, we are conducting further safety assessments
to confirm the nontoxicity of SmartPAN.
We used the ratio of drainage amylase: normal
serum amylase and repeated SmartPAN application
at relaparotomy as prognostic indicators of pancreatic
leakage. Greater levels of amylase in the abdominal
drainage fluid were consistently observed in animals
from leakage-uncorrected pigs, which coincide with
expectations following initial surgery. While these bio-
chemical differences did not reach statistical signifi-
cance, possibly due to disproportionate group
numbers and small sample size, their relevance is
supported by findings at relaparotomy. Leakage-
uncorrected pigs showed early clinical signs of POPF,
whereas leakage-corrected and indicator-negative pigs
did not. This suggests a correlation between heightened
drainage amylase and early clinical signs of POPF. It is
important to reiterate at this stage that the value and
reliability of the amylase data in this study are in ques-
tion because guidelines suggest that amylase levels
should be tracked for a minimum of three days to be
diagnostic of a leakage. Additionally, concerns with
group imbalance and cohort size make intergroup com-
parison impossible. The POPF predictive capabilities
of SmartPAN will thus be the subject of future studies.
Conclusions
The pancreatic fluid indicator described in this study
may meet the need for intraoperative control of com-
plications during PR. SmartPAN is simple to use and
provides clear, localized, and rapid responses to pan-
creatic fluid. It may facilitate refined closure of the pan-
creatic remnant and adoption of appropriate
postoperative management in order to reduce the risk
of POPF. The findings of this study justify further
investigation of SmartPAN’s clinical value.
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